Abstract With the advent of long-acting anti-vascular endothelial growth factor substances, “healing AMD (age-related macular degeneration)” might be easily assumed due to prolonged treatment intervals. Adoption oncological concept minimal residual disease for quiescent choroidal neovascularization (CNV) lesions enhance importance continued monitoring, and spur research into core disease, i.e.,...